Vistin Pharma ASA: First quarter 2025 financial results

25 Apr 2025 07:35 CEST

Oslo, Norway, 25(th) of April 2025

Vistin Pharma ASA (VISTN) today announces the financial results for the first
quarter of 2025.

Revenue in the first quarter ended at MNOK 115 compared to MNOK 104 in Q1 2024.
Sales volume in the quarter was up by 14% compared to same quarter last year.

First quarter EBITDA ended at MNOK 30 compared to MNOK 20 in Q1 2024, an
increase of 48%. EBITDA positively affected by increased sales volume and
product mix in the quarter, in addition to continues focus on cost improvements.

The net profit ended at MNOK 21.7 (MNOK 7.7) for the first quarter of 2025.
While net cash position as of end March was MNOK 13.

Operational performance in the quarter was good with 1 350MT produced. The
reactor on line 1 has been replaced during March according to maintenance plan
due to end of its life span. Without reactor replacement and the idle downtime
on line 1, the run-rate equaled ~1 500 MT in the quarter. Line 1 was also partly
idle during first two weeks of April.

Vistin is currently seeing no changes in demand from customers after the US
tariff announcements.

The Board of Directors has proposed for the AGM an ordinary dividend of total
NOK 1.25 per share, to be paid in June.

The first quarter conference call, which will be held today 25th of April at
8.30am (CET), will be available via webcast and audio through the following
access points:

Webcast:
https://edge.media-server.com/mmc/p/9g56ohth
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fedge.media-
server.com%2Fmmc%2Fp%2F9g56ohth&data=05%7C02%7CAlexander.Karlsen%40vistin.com%7C
cd63feffa5b24af9d8ce08dd6ba9d720%7C2fcdf060b2c2456e8bb7944b7e40981a%7C0%7C0%7C63
8785100003206993%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDA
wMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=TZ%2B5l
QKr0hsPrLA8vXsxn3ytEE3Vd4vC1WFcutlpoyY%3D&reserved=0)

Telephone conference (online registration):
https://register-conf.media-
server.com/register/BI532205913f1d42059d747081a631bec9
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fregister-
conf.media-
server.com%2Fregister%2FBI532205913f1d42059d747081a631bec9&data=05%7C02%7CAlexan
der.Karlsen%40vistin.com%7Ccd63feffa5b24af9d8ce08dd6ba9d720%7C2fcdf060b2c2456e8b
b7944b7e40981a%7C0%7C0%7C638785100003222025%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1h
cGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D
%7C0%7C%7C%7C&sdata=MveoY6gaqdl8b6Z3lvdjCC7vejoFmXNoKIvyTnxcA%2FI%3D&reserved=0)

The conference call will be held in English.

Please find the Q1 report and presentation enclosed. The report will also be
made available on www.vistin.com (http://www.vistin.com).

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com (mailto:alexander.karlsen@vistin.com)

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site

644394_Vistin Pharma ASA Q1 report 2025.pdf
644394_Vistin Pharma_Q1_25_presentation.pdf